- $5.95bn
- $10.77bn
- $5.10bn
Brief: Bausch Plan To Spin Off Eye-Care Business Stuck In Creditor Standoff- WSJ
Brief: FDA Identifies Bausch + Lomb/Synergetics Inc's Certain I-Pack Injection Kits Recall As Most Serious Type
Brief: Bausch + Lomb Launches Blink NutriTears Clinically Proven Nutritional Supplement For Dry Eyes In The United States
Brief: Bausch + Lomb Announces 2024 Annual Meeting Of Shareholder Results
Brief: Bausch+Lomb Receives Health Canada Approval For Envista Envy Lens
Brief: Bausch + Lomb Announces First-Quarter 2024 Results
Brief: Bausch + Lomb Announces Presentation Of New Data At The Association For Research In Vision And Ophthalmology Annual Meeting
Brief: Bausch + Lomb Receives FDA Approval Of LUMIFY
Brief: Bausch + Lomb Announces Statistically Significant Results From Clinical Study Of Novel Daily Nutritional Supplement
Medical device makers fall after J&J's medtech unit misses sales estimates
Bausch wins US appeal to block Alvogen generic of diarrhea drug
Brief: Bausch + Lomb Appoints Karen Ling To Board Of Directors
Bausch + Lomb's U.S. shares tracking record gain after Q4 beat
Emergent rises after naming former Bausch + Lomb head as CEO
Brief: Emergent BioSolutions Appoints Industry Leader Joseph C. Papa As New President And CEO
U.S. STOCKS ON THE MOVE-Emergent BioSolutions, Intuitive Machines, Garmin Ltd
Emergent rises after naming former Bausch + Lomb top boss as CEO
Emergent appoints former Bausch + Lomb CEO to head company (updated)
Emergent names Joseph Papa as new CEO